Otelixizumab: A novel agent for the prevention of type 1 diabetes mellitus

Expert Opinion on Biological Therapy

Volumn 11, Issue 11, 2011, Pages 1525-1532

  Miller, Shannon A ^a   St Onge, Erin ^b  

^a FLORIDA HOSPITAL   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Anti CD3 antibody; Otelixizumab; Prevention of type 1 diabetes mellitus

Indexed keywords

AZATHIOPRINE; BCG VACCINE; C PEPTIDE; CYCLOSPORIN; DENILEUKIN DIFTITOX; ETANERCEPT; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE 65; GLYCOSYLATED HEMOGLOBIN; INSULIN; INTERLEUKIN 6; MYCOPHENOLIC ACID; NICOTINAMIDE; OMEGA 3 FATTY ACID; OTELIXIZUMAB; RITUXIMAB; TEPLIZUMAB; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

AGE; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CELL REGENERATION; CERVICAL LYMPHADENOPATHY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MONONUCLEOSIS; MYALGIA; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; REGULATORY T LYMPHOCYTE; SORE THROAT; SURFACE PLASMON RESONANCE; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; HUMANS; HYPOGLYCEMIC AGENTS; TREATMENT OUTCOME;

EID: 80053637673     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.610789     Document Type: Article

References (44)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf [Last accessed 4 August 2011]
2. Diabetes Statistics. Alexandria, VA: American Diabetes Association, 2011. Available from: http://www.diabetes.org/diabetes-basics/diabetes-statistics [Last accessed 4 August 2011]
3. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-9 (Pubitemid 32718550)
4. Pugliese A. Unraveling the genetics of insulin-dependant type 1A diabetes: the search must go on. Diabetes Rev 1999;7:39-54 (Pubitemid 29137711)
5. Gepts W, Lecompte P. The pancreatic islets in diabetes. JAMA 1981;70:105-15
6. Schranz DB, Lernmark A. Immunology in diabetes. An update. Diabetes Metab Rev 1998;14:3-29
7. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965;14:619-33
8. Petrovsky N, Silva D, Schatz D. Prospects for the prevention and reversal of type 1 diabetes mellitus. Drugs 2002;62:261-75
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34:S62-9
10. Raskin P, Mohan A. Emerging treatments for the prevention of type 1 diabetes. Expert Opin Emerg Drugs 2010;15:225-36
11. Barnett AH, Eff C, Leslie RD, et al. Diabetes in identical twins. A study of 200 pairs. Diabetologia 1981;20:87-93 (Pubitemid 11138466)
12. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-20
13. Hummel M, Fuchtenbusch M, Schenker M, Ziegler AG. No major association of breast-feeding, vaccinations, and childhood viral diseases with early islet autoimmunity in the German BABYDIAB Study. Diabetes Care 2000;23:969-74 (Pubitemid 30480025)
14. Cainelli F, Manzaroli D, Renzini C, et al. Coxsackie B virus-induced autoimmunity to GAD does not lead to type 1 diabetes. Diabetes Care 2000;23:1021-2 (Pubitemid 30480036)
15. American Diabetes Association. Standards of Medical Care in Diabetes-2011. Diabetes Care 2011;34:S11-61
16. Gandhi GY, Murad MH, Flynn DN, et al. Immunotherapeutic agents in type 1 diabetes: a systematic review and meta-analysis of randomized trials. Clin Endocrinol 2008;69:244-52 (Pubitemid 352009018)
17. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011;3:76-99
18. Hale G, Rebello P, Bakir I, et al. Pharmacokinetics and antibody response to the CD3 antibody otelixizumab used in the treatment of type 1 diabets. J Clin Pharmacol 2010;50:1238-48
19. Wiczling P, Rosenzweig M, Vaickus L, et al. Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-cd3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus. J Clin Pharmacol 2010;50:494-506
20. Chatenoud L, Thervert E, Primo J, et al. Anti-CD3 antibody induces long term remission of overt autoimmunity in nonobese diabetic NOD mice. Proc Natl Acad Sci USA 1994;91:123-7 (Pubitemid 24018655)
21. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997;158:2947-54 (Pubitemid 127470558)
22. Belgith M, Bluestone JA, Barriot S, et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003;9:1202-8 (Pubitemid 37173706)
23. Masharani UB, Becker J. Teplizumab therapy for type 1 diabetes. Expert Opin Biol Ther 2010;10:459-65
24. Keymeulen B, Vandemeulebroucke E, Ziegler A, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-608 (Pubitemid 41007846)
25. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomized controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010;53:614-23
26. Bresson D, Togher L, Rodrigo E, et al. Anti-CD3 and nasal proinsulin in combination therapy enhances remission from recent onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006;116:1371-81
27. Cook JJ, Hudson I, Harrison LC, et al. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 1989;38:779-83 (Pubitemid 19285733)
28. Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010;33:826-32
29. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-52
30. Study of Thymoglobulin to Arrest Type 1 Diabetes (START). San Francisco, CA: Immune Tolerance Network. Available from: http://immunetolerance.org/ studies/starttrial [Last accessed 4 August 2011]
31. Karounos DG, Bryson JS, Cohen DA. Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice. J Clin Invest 1997;100:1344-8 (Pubitemid 27425758)
32. Boitard C, Timsit J, Assan R, et al. Treatment of type 1 diabetes mellitus with DAB486-IL-2, a toxin conjugate which targets activated T-lymphocytes. Diabetologia 1992;35:A218
33. Ludvigsson J, Faresjo M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359(18):1909-20
34. Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005;19:238-46 (Pubitemid 40910206)
35. Shehadeh N, Calcinaro F, Bradley BJ, et al. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 1994;343:706-7 (Pubitemid 24087852)
36. Diabetes Care.Net. Promising Results of Phase I Type 1 Diabetes Trial Announced. Available from: www.diabetescare.net/flash-article.asp?id=445554 [Last accessed 10 August 2011]
37. Raz I, Elias D, Avron A, et al. beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001;358:1749-53 (Pubitemid 33152998)
38. Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009;32:1244-9
39. Gale EA, Bingley PJ, Emmett CL, et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363:925-31
40. Hypponen E, Laara E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001;358:1500-3 (Pubitemid 33055701)
41. Norris JM, Yin X, Lamb MM, et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes JAMA 2007;298:1420-8
42. Herold K, Gitelman SE, Masharani U, et al. A single course of Anti-CD3 monoclonal antibody hOKT3gamma1 (Ala-Ala) results in improvement in c-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabets. Diabetes 2005;54:1763-9 (Pubitemid 40770766)
43. Tolerx Inc; Juvenile Diabetes Research Foundation Durable-response therapy evaluation for early or new-onset Type 1 diabetes-DEFEND. ClinicalTrials.gov; NCT00678886. Available from: clinicaltrials.gov/ct2/show/ NCT00678886
44. Tolerx Inc; Juvenile Diabetes Research Foundation; Glaxo Smithkline DEFEND 2: Durable-response therapy evaluation for early-or new-onset Type 1 diabetes. ClinicalTrials.gov; NCT01123083. Available from: clinicaltrials.gov/ ct2/show/NCT01123083